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Background. Obesity and metabolic syndrome (MetS) are major risk factors for atherosclerotic diseases; however, a causal link
remains elusive. Animal models resembling human MetS and its complications, while important, are scarce. We aimed at
developing a porcine model of human MetS. Methods. Forty pigs with familial hypercholesterolemia were fed a high fat
+ fructose diet for 30 weeks. Metabolic assessments and subcutaneous fat biopsies were obtained at 18 and 30 weeks, and fat
distribution was assessed by CT-scans. Postmortem, macrophage density, and phenotype in fat tissues were quantiﬁed along
with atherosclerotic burden. Results. During the experiment, we observed a >4-fold in body weight, a signiﬁcant but small
increase in fasting glucose (4.1mmol/L), insulin (3.1mU/L), triglycerides (0.5mmol/L), and HDL cholesterol (2.6mmol/L).
Subcutaneous fat correlated with insulin resistance, but intra-abdominal fat correlated inversely with insulin resistance and LDL
cholesterol. More inﬂammatory macrophages were found in visceral versus subcutaneous fat, and inﬂammation decreased in
subcutaneous fat over time. Conclusions. MetS based on human criteria was not achieved. Surprisingly, visceral fat seemed part
of a healthier metabolic and inﬂammatory proﬁle. These results diﬀer from human ﬁndings, and further research is needed to
understand the relationship between obesity and MetS in porcine models.
1. Introduction
Metabolic syndrome (MetS) is a cluster of insulin resistance
(IR), impaired glucose tolerance, dyslipidemia (high triglyc-
erides, low high-density lipoprotein cholesterol (HDL-C)),
and hypertension often accompanying obesity. Especially,
IR is considered a central part of MetS and type 2 diabetes,
although the mechanisms are not fully understood [1].
Because MetS and type 2 diabetes in humans are associated
with atherosclerotic cardiovascular disease, such as myocar-
dial infarction, stroke, and peripheral artery disease, there is
a constant interest in animal models of MetS and type 2
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diabetes, with potential in translational research [2]. Such
animal models must ideally combine atherosclerosis and type
2 diabetes, as these outcomes are ultimately of interest to
understand and prevent in humans.
Recently, porcine models of MetS have gained attention.
However, the task has proven demanding, as only select
breeds develop more than trivial changes in MetS parameters
and none develop frank type 2 diabetes in response to
overfeeding and obesity [3–9]. This is depicted in Table 1
where a sample of current porcine models of MS is displayed.
While some secondary detrimental eﬀects of obesity have
been observed, for example, nonalcoholic fatty liver disease
[10, 11], it has not been demonstrated that obesity and met-
abolic changes in porcine models accelerate atherosclerosis.
It should be noted that the studies in Table 1 diﬀer on
several key design parameters such as diet, duration, weight,
and number of pigs and serve as an overview rather than
strict comparison.
Inhumans, chronic low-grade inﬂammation involving the
adipose tissue (AT) is believed to play a pivotal role in the
development of MetS [12–14]. AT expansion is followed by
macrophage inﬁltration, formation of crown-like structures,
and increased inﬂammatory markers in plasma [15–20].
While obesity generally correlates with IR and type 2 diabetes,
there is a stronger correlationbetween, speciﬁcally, visceralAT
expansion and IR [1, 14, 21–23]. Whether porcine models of
MetS display a similar pattern of inﬂammation and IR is
currently unknown.
We investigated 40 minipigs known to develop human-
like atherosclerosis spontaneously [24] and assessed the
metabolic eﬀects of a high fat + fructose diet (HFF) fed for
30 weeks. The pigs were part of a study investigating the
eﬀects of MLDL1278A, a human antibody against oxidized
apolipoprotein B [25]. In this paper, we present the eﬀects
of obesity on the metabolic parameters used to deﬁne
MetS in this porcine model. We also show the associations
between obesity, atherosclerosis, and MetS parameters, and
we report the inﬂammatory proﬁle and distribution of ATs
in these pigs. The diﬀerences and similarities to human
pathology are relevant to consider in translational research
in obesity and MetS.
2. Material and Methods
Forty atherosclerosis-susceptible familial hypercholesterol-
emia Bretoncelles Meishan (FBM) pigs were included in this
study. FBM pigs have defective low-density lipoprotein
(LDL) receptors and are prone to develop hyperlipidemia
and atherosclerosis on high cholesterol diet [24]. In human
females, menopause is an independent risk factor for MetS
Table 1: Current competing porcine models of metabolic syndrome.
Ossabaw pig 3 Göttingen pig 5 Iberian pigb 4
Obese group Obese group Obese group
Obesogenic diet
2.0% cholesterol, 17%
hydrogenated soybean oil,
2.3% corn oil, 0.7% sodium
cholate
32% crude fat, 17% protein
Ad libitum: 3.7% saturated fat,
2.8% polyunsaturated fat,
15.1% crude protein
Control diet
Lean group Lean group Lean group
Standard chow Standard chow Standard chow
Lean (n = 9) Obese (n = 8) Lean (n = 6) Obese (n = 6) Lean (n = 4) Obese (n = 6)
Duration 9 weeks 5 weeks 100 days
Weight (kg) 29 45a∗ 21 27a∗ 209 251a∗
Fasting glucose (mmol/L) <5.5 <5.5 4.4 4.5 <4.4 <4.4
Fasting insulin (mU/L) <20 <20 11 14 <1 <1
HOMA-IR — — 2.1 2.9 <0.3 <0.3
Insulin AUCc (mU/L×min) 2579 3811∗ 1923 2895∗ — —
Glucose AUCc (mmol/L×min) NS NS 578 636 — —
Systolic blood pressure (mmHg) 113 137 — — 150 170a
Diastolic blood pressure (mmHg) 70 92 — — 95 115∗
Mean blood pressure (mmHg) 79 107∗ — — 112 137∗
Triglycerides (mmol/L) 0.42 0.57∗ 0.13 0.24∗ 0.24 0.32∗
Cholesterol
Total (mmol/L) 4.1 12.4∗ 1.8 2.0 1.7 2.9∗
HDL (mmol/L) 1.2 1.0a 0.8 1.0∗a 0.8 0.72a
LDL (mmol/L) 2.7 11∗ — — 1.2 1.6∗
LDL/HDL ratio 2.5 11∗ — — 1.5 2.3∗
NS: data not provided but reported as nonsigniﬁcant diﬀerence. aChanges fulﬁll human criteria of metabolic syndrome. bAll data points read from published
ﬁgures. cIVGTT in all but Iberian pig (oral GTT). 60 minutes AUC in Ossabaw pigs and 120min AUC in Göttingen and Iberian pigs 2 g/kg orally; ∗p < 0 05.
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[26] and our pigs were all castrated females. The pigs were
fed regular chow from birth until aged 6–11 months, after
which they were fed ad libitum, 8 hours a day, for 7-8
months with a custom-made, calorie-dense HFF diet, con-
sisting of 2% cholesterol, 22% fat (lard), and 18% fructose
(Supplementary Figure 2). Following the development of
severe obesity, the eﬀect of a potential antiatherosclerotic
drug (MLDL1278A) was tested in 20 pigs, while 20 pigs
received placebo as previously reported [25]. Two pigs were
excluded due to severe chronic lung disease discovered dur-
ing autopsy, and in one this was also found in a computed
tomography (CT) scan performed 12 weeks prior. Metabolic
assessments were performed at three weeks before HFF diet,
that is, W(−3), and at 18 weeks (W18) and 30 weeks (W30)
on HFF diet as outlined in Table 2 and detailed in the online
supplementary information (SI) (available here). The study
was conducted in accordance with ILAR’s “Guide for the
Care and Use of Laboratory Animals,” and the Danish Ani-
mal Experiments Inspectorate approved the study.
2.1. Intravenous Glucose Tolerance Test (IVGTT). Central
and peripheral venous catheters were placed via the jugular
vein and in the auricular vein, respectively, in 7 pigs at
W(−3) before HFF diet and in all 40 pigs at time points
W18 and W30 as previously described [25] (Table 2). After
an overnight fast, with the catheters in place, the pigs were
transferred to a containment cage. They settled for 20–30
minutes, and 3 baseline blood samples were collected to
determine fasting insulin, glucose, and lipid levels. A glucose
bolus (500mg/kg) was infused through the peripheral venous
catheter, and blood samples were drawn from the central
venous catheter after 5, 10, 20, 30, and 60 minutes (SI).
We calculated the area under the curve (AUC) follow-
ing glucose infusion and the homeostatic model assess-
ment of insulin resistance (HOMA-IR) [27] from the fasting
baseline values. We also computed the calculated insulin
sensitivity index (CSI) [28]. This was done using a minimally
modiﬁed formula:
CSI =
KG
ΔAUCINS/ΔT
, 1
where KG is the glucose disposal rate (the slope of log[glu-
cose]) from 5 to 60 minutes after glucose infusion, ΔAUCINS
is the AUC of insulin above baseline, and ΔT is equal to 55
minutes (modiﬁed from 40 in the original formula).
Due to technical diﬃculties, observations from 3 pigs
(1 drug, 2 placebo) were excluded from the W18 samples.
The 7 IVGTTs performed at time point W(−3), before
HFF diet, were conducted at another facility, and the pro-
cedure diﬀered in regard to handling and venous catheter
placement (SI).
2.2. Assessment of Obesity and Adipose Tissue Distribution.
Whole-body computed tomography (CT) scans were
performed on all pigs 1–8 days prior to euthanization as
described by Val-Laillet et al. [29] (see SI and Supplementary
Figure 3). We measured intra-abdominal, subcutaneous AT,
and total cross section. “Lean tissues” was obtained by sub-
tracting total AT from the total cross section (Supplementary
Figure 4). CT data ﬁles from one pig, in the placebo group,
became corrupt and could not be analyzed.
2.3. Lipid Proﬁling. Fasting blood samples for assessment of
total cholesterol, LDL cholesterol (LDL-C), HDL-C, and tri-
glycerides were obtained at baseline before HFF diet W(−3)
and after 18 and 30 weeks on HFF, W18 and W30. This
was measured during the IVGTT procedure prior to glucose
bolus (Table 2 and SI) [25].
2.4. Blood Pressure. Blood pressure was measured noninva-
sively before central venous catheter placement (time points
T3 and T4) using an automated sphygmomanometer on
the tail artery measuring heart rate and systolic, diastolic,
and mean arterial pressure (SI).
2.5. Adipose Tissue and Inﬂammation. Subcutaneous AT was
obtained at W18 and W30 by sample excision in the gluteal
area of anesthetized pigs (for details see SI). In addition, at
W30, we analyzed perivascular AT adjacent to the left ante-
rior descending coronary artery (LAD), mesenteric AT in
relation to the small intestine, and extraperitoneal AT. Peri-
vascular AT sections were chosen based on the LAD site with
the largest atherosclerotic plaque. Tissue sections were
blinded for group (drug versus placebo). Macrophage pheno-
type was assessed by immunohistochemistry using two mac-
rophage markers: CD163, a type B scavenger receptor and an
anti-inﬂammatory macrophage-speciﬁc marker [30], and
cathepsin S (CatS), a cysteine protease found in phagocytic
Table 2: Study timeline. Varying metabolic assessments performed at time pointsW(−3) toW(30). AtW(−3), we performed IVGTT on n = 7
pigs. At W18, we performed IVGTT and subcutaneous fat biopsies on all pigs. At W30, we performed IVGTT, extra- and intra-abdominal fat
biopsies, and full-body computed tomography scans on all pigs.
W(−3) W0 W18 W30
Age in weeks 0 29 35 38 56 68
Diet Chow HFFD
Intervention Castration Drug trial (MLDL1278A) CT-scans
Fasting lipids (N = 38) Fasting lipids (N = 38) Fasting lipids (N = 38)
IVGTT (N = 7) IVGTT (N = 37) IVGTT (N = 38)
Blood pressures Blood pressures
Subcutaneous AT biopsies Subcutaneous AT biopsies
Necropsy
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cells and a proinﬂammatory serum marker associated with
IR [31–33], inﬂammation, and atherosclerosis [34]. Five ran-
dom high-power-ﬁeld images were taken through a 20x
objective using a camera-mounted microscope. The image
ﬁles were then blinded for adipose tissue compartment, and
positive cells were identiﬁed by applying a color threshold
and counted in ImageJ (National Institutes of Health).
Crown-like structures were deﬁned as >50% of an adipocyte
circumference occupied by CatS-positive cells or >3 CatS-
positive cells encircling an adipocyte (SI). We visually
searched through each image of the CatS slides and noted
if there were any crown-like structure present [16, 35]
(for details see SI).
2.6. Quantiﬁcation of Atherosclerosis. The aorta, the right
coronary artery, and the left iliac artery were stained en face
with Sudan IV, and atherosclerosis burden was quantiﬁed
as intimal surface lesion area in percentages of total vessel
wall area [25, 36].
2.7. Statistical Analyses. Analyses were performed using
GraphPad Prism® (GraphPad Software Inc., CA, USA) and
STATA® (StataCorp LP, TX, USA). Between group compar-
isons were done using Student’s t-test, Mann–Whitney test,
or Wilcoxon matched-pairs signed rank test as appropriate.
In one instance, multiple comparisons were tested using
Kruskal-Wallis and corrected with Dunn’s posttest (the
inﬂammatory proﬁle of the diﬀerent AT). Correlations were
computed using multivariable linear regression analyses,
where the heteroscedasticity consistent covariant matrix
was applied to obtain robust standard errors [37]. Before
combining the two groups (drug versus placebo), slopes
and intersects were tested for signiﬁcance in traditional
univariable regression. No diﬀerences were found. Statisti-
cal signiﬁcance was accepted at p < 0 05, and trend was
deﬁned as p < 0 1.
3. Results
Because we found no eﬀect of the drug on any of the param-
eters we investigated in this study, the drug and placebo
groups were combined for further analyses, to increase statis-
tical power. For an overview of the metabolic parameters, see
Table 3. A comparison of three other porcine models of
human MetS [3–5] is provided in Table 1.
3.1. Body Weight and Obesity. On regular chow, the pigs
weighed 25.6 (±12.7, SD) kg on average and the weight
increased to 112.3 (±20.8, SD) kg following 30 weeks on the
diet (Table 3, Figure 1(a)). CT scans prior to euthanization
showed that the high weight was predominately driven by
fat gain as shown in Figure 1(b), where fat tissue represented
60% of the abdominal cross section, interquartile range
(57%–64%).
Table 3: Characteristics of metabolic parameters in the FBM pigs.
FBM pig
Obesogenic diet Ad libitum: 2.0% cholesterol, 22% fat (lard), 18% fructose
Control diet No control diet
W(−3) W18 W30
(n = 38)
Duration
33 weeks
12 weeks
Weight (kg) 25.6 87 112∗
Fasting glucose (mmol/L) 3.9 (3.7–4.2) 4.1∗ (3.9–4.3)
Fasting insulin (mU/L) 2.6 (2.2–3.2) 3.1∗ (2.5–4.4)
HOMA-IR 0.46 (0.36–0.58) 0.57∗ (0.43–0.86)
Insulin AUC (mU/L×min) 862 (671–1048) 1189∗ (915–1463)
Glucose AUC (mmol/L×min) 862 (±15) 948 (±17)∗
Systolic blood pressure (mmHg) 141 (127–150) 131∗ (113–141)
Diastolic blood pressure (mmHg) 68 (±13) 66 (±14)
Mean blood pressure (mmHg) 93 (86–101) 91 (73–97)
Triglycerides (mmol/L) 0.4 (0.4–0.5) 0.5∗ (0.4–0.8)
Cholesterol
Total (mmol/L) 4.1 (±0.3) 16 (±1.1)∗
HDL (mmol/L) 0.7 (±0.1) 2.6 (±0.3)∗
LDL (mmol/L) 3.1 (2.4–3.8) 14∗ (11–15)
LDL/HDL ratio 3.9 (2.8–5.7) 5.4∗ (3.6–7.5)
For detailed statistical information, see supplementary information. Data is presented as mean (±SD) or median (interquartile range) where appropriate;
∗p < 0 05.
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During the ﬁnal 12 weeks of the study (from W18
to W30), there was a statistically signiﬁcant increase in
body weight, fasting glucose and insulin, HOMA-IR, and
AUCs for glucose and insulin (Table 3 and Supplementary
Table 1). Similarly, CSI decreased signiﬁcantly by 22%
(p = 0 001, Supplementary Table 1).
Three weeks prior to HFF diet, W(−3), we performed
IVGTT on 7 pigs in a diﬀerent facility from that in W18
andW30. Here, we found a discrepancy between the changes
in fasting and IVGTT measurement over time, and that fast-
ing glucose, but not HOMA-IR, decreased while CSI also
decreased (Supplementary Table 1).
3.2. Relationship of Obesity and Insulin Resistance. By incor-
porating Val-Laillet’s method of quantifying fat depots by CT
scan, we were able to obtain reliable measures of obesity, evi-
dent through a strong correlation between weight and
abdominal CT cross section (R2 = 0 74, Figure 2). Similarly,
in multivariable regression, weight was strongly, and inde-
pendently, correlated to intra-abdominal AT, subcutaneous
AT, and lean tissue (R2 = 0 76, Table 4).
The above parameters of obesity were correlated to IR in
multivariable regression models. Surprisingly, we found that
subcutaneous AT showed an independent direct correlation,
while intra-abdominal AT showed an independent inverse
correlation with HOMA-IR. Lean tissues did not correlate
with HOMA-IR (p = 0 49, Table 4, Figure 3) nor did total
body weight (p = 0 61). When fat depots were normalized
to total CT cross section, the correlations were strengthened
for subcutaneous AT (p = 0 01) as well as intra-abdominal
AT (p = 0 038) with R2 = 0 20.
Subcutaneous AT but not intra-abdominal AT (p = 0 20)
correlated inversely to CSI in a two-variable regression
model. Adding lean tissues to the model did not improve
the correlations, and weight did not signiﬁcantly correlate
with CSI (p = 0 078). Excluding the two insigniﬁcant vari-
ables resulted in a univariable model of CSI versus subcutane-
ous AT as shown in Table 4.
When fat depots were normalized to total CT cross sec-
tion, the inverse correlation between subcutaneous AT and
CSI was strengthened (p = 0 010, R2 = 0 19) but remained
insigniﬁcant for intra-abdominal AT and CSI (p = 0 58).
3.3. Lipid Proﬁle. Compared to regular chow, HFF diet led to
a substantial increase in total cholesterol, LDL-C, and HDL-
C and a smaller increase in the LDL-C/HDL-C ratio and tri-
glycerides (Table 3). Only small changes were seen during the
ﬁnal 12 weeks of the study. Lipid data is detailed in a previous
publication [25].
Interestingly, we found that intra-abdominal AT, but not
subcutaneous AT, correlated inversely with LDL cholesterol
as well as total cholesterol (Table 4). No such correlation
was found between obesity and triglycerides (p > 0 3).
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3.4. Blood Pressure. In the 12 weeks between W18 and
W30, the systolic blood pressure declined from 141 to
131mmHg (p = 0 016; Table 3, Supplementary Table 1).
Heart rate and diastolic and mean blood pressures did
not change.
Subcutaneous AT was inversely correlated with mean
arterial pressure (p = 0 043), and intra-abdominal AT
trended towards a direct correlation with mean arterial pres-
sure (p = 0 057).
3.5. Adipose Tissue and Inﬂammation. To quantify macro-
phages and to estimate the inﬂammatory proﬁle of the ATs,
we used CD163 and CatS as described above. We found nei-
ther a signiﬁcant eﬀect nor trend for an eﬀect of MLDL1278A
on the expression of CD163 or CatS in any of the AT com-
partments (data not shown).
During the ﬁnal 12 weeks, CD163-positive cells increased
in subcutaneous AT (p = 0 02) with a trend for reduction in
CatS-positive cells (p = 0 07; see Figure 4(a)). This indicates
a polarization of subcutaneous AT in an anti-inﬂammatory
direction in response to ongoing obesity. Remarkably, at
euthanization, mesenteric AT was characterized by a
relatively low inﬂammatory cell count. We found a signiﬁ-
cantly lower density of CatS-positive cells and a signiﬁcantly
higher density of CD163-positive cells compared with subcu-
taneous AT (Figure 4(b)). Perivascular AT surrounding
atherosclerotic lesions contained a substantially higher den-
sity of CD163-positive cells compared with the other adipose
tissue compartments (>30-fold) (Figures 4(b) and 5(c)).
From the entire CatS data set comprising 38 pigs with 4
AT compartments per pig and 5 high-power ﬁelds per com-
partment, surmounting to approximately 760 high-power
ﬁelds, we only found 19 crown-like structures in 18 high-
power ﬁelds, an average of 1.45 crown-like structures/mm2.
Figure 5 shows slides of subcutaneous and perivascular AT
with representative numbers of stained cells.
3.6. Relationship of Obesity, HOMA-IR, and CSI to
Atherosclerosis. We performed two sets of multivariable
regression with atherosclerosis data. First, we correlated the
disease burden, as quantiﬁed by en face, of each vessel bed
(aorta, right coronary artery, and left iliac artery) against
HOMA-IR, CSI, and cholesterol. In this setting, cholesterol
but not HOMA-IR nor CSI correlated with atherosclerosis
burden. The correlation was signiﬁcant between cholesterol
and atherosclerosis in the aorta (p = 0 002; R2 = 0 13) and
trending for the iliac and right coronary arteries (p < 0 1).
Next, we correlated the atherosclerosis burden of each vessel
bed against intra-abdominal and subcutaneous AT. There
were no independent correlations, consistently p > 0 3 (data
not shown).
Table 4: Adipose tissues and metabolic correlations.
Model Coeﬃcients Unit Robust SE p value R2
Weight = a ∗ subcutaneous AT+ b ∗ intra-abdominal AT+ c ∗ lean tissues + k
a 0.15 kg/cm2 0.032 0.008 0.76
b 0.076 kg/cm2 0.027 0.000
c 0.10 kg/cm2 0.026 0.000
k −30.9 kg 16.3 0.067
CSI = a ∗ subcutaneous AT+ k
a −3.10E− 05 au 1.36E− 5 0.029 0.15
k 0.031 au 0.0065 0.000
HOMA-IR = a ∗ subcutaneous AT+ b ∗ intra-abdominal AT+ k
a 0.0014 au 0.00052 0.013 0.11
b −0.0017 au 0.00081 0.040
k 0.55 au 0.22 0.018
LDL-C = a ∗ subcutaneous AT+ b ∗ intra-abdominal AT+ k
a 0.0021mmol/(L·cm2) 0.0054 0.693 0.16
b −0.019mmol/(L·cm2) 0.0077 0.019
k 18.2mmol/L 1.98 0.000
Total cholesterol = a ∗ subcutaneous AT+ b ∗ intra-abdominal AT+ k
a 0.0026mmol/(L·cm2) 0.0058 0.658 0.18
b −0.024mmol/(L·cm2) 0.0091 0.013
k 22.58mmol/L 2.65 0.000
Mean arterial pressure = a ∗ subcutaneous AT+ b ∗ intra-abdominal AT+ k
a −0.077mmHg/cm2 0.036 0.043 0.12
b 0.10mmHg/cm2 0.052 0.057
k 89.0mmHg/cm2 16.4 0.000
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4. Discussion
After 30 weeks on nearly ad libitum HFF diet, the pigs
became severely obese with >4-fold increased body weight
and a predominant fat distribution of 60% (Figure 1(b)).
We observed signiﬁcant but small increases in fasting glu-
cose, total cholesterol, LDL-C, HDL-C, and triglycerides.
However, except for obesity, no parameters met the diagnos-
tic criteria for human MetS, including IR and hypertension
[1]. While the cutoﬀ values of MetS parameters may very well
diﬀer between humans and pigs, or even between breeds,
these physiological diﬀerences are important to explore
further. In contrast to humans, intra-abdominal AT was
not directly correlated with any MetS parameter. In fact, it
was inversely correlated with IR (HOMA-IR) and choles-
terol. Subcutaneous AT, on the other hand, was directly cor-
related to IR and cholesterol. In agreement with this, we
found that macrophage density and phenotype in adipose tis-
sues diﬀered from that described in human obesity and that
IR did not correlate with atherosclerosis. It has been demon-
strated that porcine models express variable metabolic
changes in response to high calorie intake and development
of obesity and may even be categorized in metabolically
healthy versus unhealthy obesity [8, 9]. The changes in MetS
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Figure 4: Macrophage polarization in adipose tissues. Number of cathepsin S-positive (a) and CD163-positive (b) cells per high-power ﬁeld
in subcutaneous AT (assessed at time point W18 and W30), mesenteric, extraperitoneal, and perivascular AT. CD163 in perivascular AT is
displayed on a separate graph due to a diﬀerence by one order of magnitude. Signiﬁcance was tested with Kruskal-Wallis and corrected with
Dunn’s posttest for multiple comparisons. ∗p < 0 05; ∗∗∗p < 0 001. Bars represent median± interquartile range.
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parameters of our obese FBM pigs are similar to those found
in other porcine models of metabolically “unhealthy” obesity
(Table 1) [8, 9]. However, the phenotypes and correlations of
obesity, inﬂammation, and IR found in the FBM pigs are dif-
ferent from human ﬁndings. This variable decoupling of obe-
sity and MetS could very well provide us with clues to the
human pathology and deserves further attention.
4.1. No Confounding Drug Eﬀects. The experimental
setup described in this paper was designed as a substudy
to one testing the eﬀects of a human antibody against
oxidized apolipoprotein B on atherosclerosis [25]. The drug
(MLDL1278A) has previously been shown to inhibit the
development of atherosclerosis and promote stabilization of
atherosclerotic plaques in mice [38, 39]. Furthermore, the
drug apparently also improved insulin sensitivity in obese
Rhesus macaques [40]. However, it failed to aﬀect atheroscle-
rosis plaque burden [25] and to meet the primary endpoint in
a phase IIa clinical trial [41]. In the current substudy (obese
pigs as model for human MetS), we found no eﬀects of the
drug on any of the components of MetS, which allowed us
to combine the treatment and placebo groups in order to
increase statistical power.
4.2. Increased Insulin Resistance but No Glucose Intolerance.
To induce IR, a substantial amount of fructose was added
to the diet [42, 43] and the pigs were fed ad libitum
in daytime hours to promote obesity. Consequently, the
FBM pigs became severely obese with an average weight of
112.3 kg at euthanization. AT accounted for ~60% of the total
abdominal area, indicating severe abdominal obesity. In
comparison, FBM pigs (castrated males) included in a previ-
ous study had a mean body weight of ~43 kg after being on a
semirestricted high-fat diet for 18 weeks [24]. At the same
age, our pigs weighed an average of 91.6 kg on HFF diet.
We used several methods to assess glucose intolerance
and IR, including fasting insulin and glucose (HOMA-IR),
IVGTT (AUC analyses), and CSI. HOMA-IR increased
by 24% over the last 12 weeks, reaching 0.59. In compar-
ison, in a general healthy nondiabetic human population,
HOMA-IR ranged from 0.63 to 4.14 (5th to 95th percen-
tiles) [44], that is, the mean HOMA-IR for our severely
obese pigs remained below the 5th percentile of nondia-
betic human subjects.
We performed IVGTT on the pigs at diﬀerent time
points. However, the baseline W(−3) measurements in a
small subgroup of pigs (n = 7) are not directly comparable
to those at W18 and W30 due to diﬀerent anesthetic and
handling procedures. These diﬀerences may explain the
small decrease in fasting glucose (12%) and concomitantly
decrease (78%) in insulin sensitivity as measured by CSI
(Supplementary Table 1).
During the ﬁnal 12 weeks of the study, body weight
increased substantially together with increasing IR (HOMA-
IR, AUCInsulin) and decreasing insulin sensitivity (CSI). How-
ever, the changes were modest, if not trivial.While AUCglucose
increased, plasma glucose still returned to baseline values 120
minutes after glucose loading (data not shown).
(a) (b)
(c) (d)
Figure 5: CD163- and CatS-positive cells in adipose tissues. (a–c) Subcutaneous (a, b) and perivascular (c) AT stained for CD163 (red) and
counterstained with hematoxylin (blue). (a) Random high-power ﬁeld with 0 positive cells. (b) Same section, after actively searching for an
area with positive cells. (c) Perivascular AT with an average number of positive cells. (d) Crown-like structure of CatS-positive cells (brown).
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The interpretation of the abovementioned changes is
complicated by the inherent pitfall of using IVGTT-based
AUC calculations to quantify IR and glucose intolerance. In
this setting, weight-adjusted glucose infusion leads to over-
dosage of obese pigs when compared to lean pigs of similar
weight due to lower water content in fat tissue versus other
tissues. Consequently, more obese pigs will have higher
AUCs for glucose and thereby also insulin. While AUC mea-
surements are less than ideal, they are the only estimation of
peripheral IR used in other porcine models. We overcame the
shortcomings of standard AUC calculations by using the CSI,
which represents glucose uptake velocity per concentration
of insulin above basal value. The CSI value is independent of
the absolute concentrations of glucose and insulin and reﬂects
the “eﬃciency” of insulin in promoting glucose uptake. The
CSI model has been validated in human subjects and shown
to correlate strongly with the gold standard euglycemic
clamp test (R2 = 0 82) [28]. While the application of CSI cal-
culation adds credibility to our ﬁndings, it demonstrates how
modest the true change in IR is in response to severe obesity.
Interestingly, feeding standard low-fat minipig chow to
Göttingen minipigs ad libitum (versus restrictively) led to
obesity with lower fasting plasma glucose and insulin and
higher insulin sensitivity [45].
4.3. Consistent Correlations between Insulin Resistance and
Fat Distribution Contrasting Human Findings. It is apparent
that not all obese humans develop MetS or cardiovascular
disease. Obesity is a heterogeneous condition, and this is
underlined by the weak correlations between insulin resis-
tance and measures of obesity (weight, BMI, fat depot sizes,
etc.) [23]. We did not expect all or most of our pigs to develop
diabetes or even MetS, but it seems reasonable to expect that
the direction of the correlations should be similar, if the
underlying pathologies were to be similar. However, our
ﬁndings were not in concordance with human studies.
In humans, visceral rather than subcutaneous AT is
considered to play the major role in the development of
obesity-related IR [1, 14, 21–23]. We found the opposite
correlations in FBM pigs where intra-abdominal AT was
inversely correlated to hepatic IR (HOMA-IR) and subcuta-
neous AT was directly correlated to both hepatic and whole
body IR (i.e., inversely to CSI). These correlations were
strengthened, when relative values were used, that is, fat
depots as percentages of entire CT cross sections.
While the correlations were weak, they were in the
same order of magnitude as similar analyses performed
in human studies [23], and they may explain why FBM
pigs are so resistant to obesity-related IR; in that, visceral
AT may not impose the same negative consequences in
FBM pigs as in humans.
We are unaware of similar correlation analyses con-
ducted in other porcine models of MetS.
4.4. Unremarkable Dyslipidemia, Mimicking Other Porcine
Models. In humans, plasma concentrations of triglycerides
and HDL-C correlate inversely [46], and the “atherogenic”
dyslipidemia commonly associated with MetS is character-
ized by raised triglycerides (>1.7mmol/L) and low HDL-C
(<0.9–1.29mmol/L). In the FBM pigs, triglycerides did
increase with obesity but remained low (mean≤ 0.5mmol/
L), and HDL-C increased substantially from 0.7mmol/L to
2.6mmol/L. High HDL-C is to be expected in pigs on a
cholesterol-rich diet, but the low triglyceride levels are
remarkable considering the high amount of fructose added
to the diet with nearly ad libitum feeding, and the successful
development of severe abdominal obesity, which, in turn, did
not correlate with triglycerides levels.
Interestingly, intra-abdominal AT seemed to correlate
inversely with LDL-C as well as total cholesterol in our
FBM pigs. While we cannot infer causality, this indicates that
intra-abdominal fat deposition in pigs is not part of a detri-
mental metabolic phenotype of obesity.
In a recent study, diet-induced obesity in Ossabaw and
Göttingen minipigs was not associated with hypertriglyc-
eridemia but only led to a nonsigniﬁcant increase in triglyc-
erides from 0.3 to 0.5mmol/L [47]. The resistance of pigs to
diet- and obesity-induced hypertriglyceridemia is not well
understood but could be related to the lack of functionally
eﬀective cholesteryl ester transfer protein (CETP) [48], extra-
hepatic lipogenesis [49], or any of the other ways; lipopro-
teins and their metabolism diﬀer in pigs and man [48, 50].
4.5. No Sign of Hypertension. With a ﬁnal blood pressure of
131/66mmHg, our severely obese pigs did not become
hypertensive according to human reference range. In fact,
the blood pressure tended to decline during the ﬁnal 12
weeks of the study. Although the reliability of tail cuﬀ mea-
surements on anesthetized pigs may be questioned, it seems
reasonable to conclude that the blood pressure did not
increase during the ﬁnal 12 weeks of the study despite a sub-
stantial increase in body weight. Remarkably, mean blood
pressure was inversely correlated to subcutaneous AT.
4.6. Surprising Inﬂammatory Phenotype in Adipose Tissues.
In this study, we found several key diﬀerences in the inﬂam-
matory proﬁle of ATs from obese FBM pigs and those
reported from human studies.
Firstly, we found a higher density of CatS-positive and a
lower density of CD163-positive cells in subcutaneous versus
mesenteric AT (a component of visceral AT). That is, there
were more proinﬂammatory and fewer anti-inﬂammatory
cells in subcutaneous compared to visceral AT.
This stands in contrast to human observations in which
visceral AT is considered more proinﬂammatory and critical
in the development of MetS [1, 14, 21].
Secondly, by repeating subcutaneous AT biopsies at W18
and W30, we found a signiﬁcant increase in anti-inﬂamma-
tory cells and a trend towards decrease in proinﬂammatory
cells during the ﬁnal 12 weeks on obesogenic diet. This indi-
cates a stagnant inﬂammatory phenotype despite ongoing
weight gain and progressive obesity.
Thirdly, we found very few CatS-positive crown-like
structures. Only 2.4% of our high-power ﬁelds had 1 or more
crown-like structures. In contrast, Bigornia et al. [51] found
CD68-positive crown-like structures in 67% of their high-
power ﬁelds from human fat using a similar high-power ﬁeld
size to ours (20x objective on a light microscope). This is
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concordant with diﬀerences in the inﬂammatory activity of
ATs between man and pig.
It appears that the intra-abdominal AT is characterized
by an anti-inﬂammatory proﬁle relative to the subcutaneous
AT. This is consistent with, and may even be causally linked
to the surprising correlations between obesity and MetS
parameters, most importantly IR. Thus, intra-abdominal
AT expansion in the pigs is seemingly part of a beneﬁcial
phenotype of obesity.
A possible explanation could be found in many porcine
strains inherent propensity towards obesity. Millenniums of
selection pressure may have lead to a healthier, more viable
phenotype of obesity with less inﬂammation and little meta-
bolic disturbance.
4.7. No Correlation between Insulin Resistance and
Atherosclerosis. Considering that MetS is a major risk factor
for atherosclerotic vascular disease in humans [2], we
expected that IR would accelerate atherogenesis and thus
correlate positively with the ﬁnal amount, or burden, of
atherosclerosis. We could however not document such an
eﬀect independent of cholesterol. These ﬁndings further
question the assumed link between inﬂammation, MetS,
and atherosclerosis in the FBM pig and call for similar
analyses to be conducted in other porcine MetS models for
a better understanding.
4.8. Strengths and Limitations. Major strengths of the study
are the large sample size and long-term nearly ad libitum
feeding with a fat-, fructose-, and energy-rich diet without
confounding cholate, leading to severe abdominal obesity.
The unusually large sample size and feeding duration led to
good statistical power, which allowed the detection of even
small changes and weak correlations. Due to the logistical cir-
cumstances of the study, a lean control group of pigs on reg-
ular diet was not included, and therefore we cannot conclude
on causality links between feeding and metabolic changes
with certainty. However, a control group is not necessary
to conclude that abdominal obesity in FBM pigs is not
associated with metabolic dysfunction. Furthermore, the
ﬁnal correlation analyses were cross-sectional in nature,
covering a wide range of body weights and obesity.
5. Conclusion
Based on the cut-points used to deﬁne MetS in humans,
severely obese FBM pigs did not meet the diagnostic criteria
for MetS despite a >4-fold weight gain. This is similar to pre-
vious ﬁndings in other obese pigs. The explanation may be
found in our data. The FBM pig expresses a diﬀerent pheno-
type of obesity with regard to inﬂammation, IR, and athero-
sclerosis compared to man. We found that intra-abdominal
AT had a lower content of proinﬂammatory cells and a
higher content of anti-inﬂammatory compared to subcuta-
neous AT. And intra-abdominal AT was correlated with a
healthier metabolic phenotype, that is, reduced IR and
cholesterol and insulin resistance did not correlate with
atherosclerosis. While porcine models of MetS would be of
great beneﬁt, these diﬀerences may explain the diﬃculties
experienced so far and a better understanding of porcine
pathophysiology is needed. We encourage future studies
to include markers of inﬂammation, fat distribution, and
the use of the calculated insulin sensitivity index (CSI) in
the assessment of porcine MetS. Our data shows funda-
mental diﬀerences in the relationship between obesity,
inﬂammation, metabolic disturbances, and atherosclerosis
in FBM pigs compared to man. A better understanding
of these factors in other porcine models may provide valu-
able insights on the human metabolic syndrome.
Abbreviations
AT: Adipose tissue
CatS: Cathepsin S
CSI: Calculated insulin sensitivity index
CT: Computed tomography
FBM: Familial hypercholesterolemia Bretoncelles
Meishan
HFF diet: High fat + fructose diet
HOMA-IR: Homeostatic model assessment of insulin
resistance
IR: Insulin resistance
LAD: Left anterior descending coronary artery
MetS: Metabolic syndrome
SI: Supplementary information
W(−3): Three weeks prior to high fat + fructose diet
W18: 18 weeks following high fat + fructose diet
W30: 30 weeks following high fat + fructose diet.
Conflicts of Interest
Björn Frendéus is a full-time employee of BioInvent Inter-
national AB, and Karin von Wachenfeldt and Anna-Karin
Robertson were employed at BioInvent at the time the study
was conducted. Søren Kragh Moestrup is a minority share-
holder of the biotech company Aﬃnicon Aps. All other
authors declare that they have no conﬂicts of interest.
Authors’ Contributions
Ahmed Ludvigsen Al-Mashhadi and Christian Bo Poulsen
contributed equally to this work.
Acknowledgments
The authors would like to thank the laboratory technicians
at the Atherosclerosis Research Unit and the personnel at
the animal research facility Paaskehøjgaard for technical
assistance throughout the study. The study was funded
by Bioinvent International (Lund, Sweden) who also pro-
vided the drug (MLDL1278A) and by the Faculty of
Health, Aarhus University.
Supplementary Materials
Supplementary Table 1: supplementary statistical results:
eﬀects of drug and time/age. Supplementary Figure 1: study
timeline—interventions and assessments. Supplementary
Figure 2: high fat + fructose diet (HFFD). Supplementary
10 Journal of Diabetes Research
Figure 3: identifying the P2 site by computed tomography
imaging. Top: 3D reconstruction of the FBM-pig spinal
column and ribcage. The red dot marks the P2 site corre-
sponding to vertebra L2 right below the last true rib. Bot-
tom: typical cross section at the L2 level of an obese FBM
pig. Supplementary Figure 4: measurement of adipose tis-
sue compartments. Left column: cross-sectional computed
tomography images at the vertebra L2 level. Right column:
thresholding binary images depicting AT (black). Top row:
total AT. Subcutaneous AT is marked as a ROI in order to
obtain the mean and SD values for AT in the pig. Middle
row: intraperitoneal AT (visceral AT). Bottom row: intra-
abdominal AT. (Supplementary Materials)
References
[1] C. Day, “Metabolic syndrome, or what you will: deﬁnitions
and epidemiology,” Diabetes and Vascular Disease Research,
vol. 4, no. 1, pp. 32–38, 2016.
[2] S. Mottillo, K. B. Filion, J. Genest et al., “The metabolic syn-
drome and cardiovascular risk a systematic review and meta-
analysis,” Journal of the American College of Cardiology,
vol. 56, no. 14, pp. 1113–1132, 2010.
[3] M. C. Dyson, M. Alloosh, J. P. Vuchetich, E. A. Mokelke, and
M. Sturek, “Components of metabolic syndrome and coronary
artery disease in female Ossabaw swine fed excess atherogenic
diet,” Comparative Medicine, vol. 56, no. 1, pp. 35–45, 2006.
[4] L. Torres-Rovira, S. Astiz, A. Caro et al., “Diet-induced swine
model with obesity/leptin resistance for the study of metabolic
syndrome and type 2 diabetes,” The Scientiﬁc World Journal,
vol. 2012, Article ID 510149, 8 pages, 2012.
[5] T. Johansen, H. S. Hansen, B. Richelsen, and R. Malmlöf,
“The obese Göttingen minipig as a model of the metabolic
syndrome: dietary eﬀects on obesity, insulin sensitivity, and
growth hormone proﬁle,” Comparative Medicine, vol. 51,
no. 2, pp. 150–155, 2001.
[6] D. A. Bellinger, E. P. Merricks, and T. C. Nichols, “Swine
models of type 2 diabetes mellitus: insulin resistance, glucose
tolerance, and cardiovascular complications,” ILAR Journal,
vol. 47, no. 3, pp. 243–258, 2006.
[7] W. T. Cefalu, “Animal models of type 2 diabetes: clinical
presentation and pathophysiological relevance to the human
condition,” ILAR Journal, vol. 47, no. 3, pp. 186–198, 2006.
[8] S.-J. Li, C.-H. Liu, C.-W. Chang et al., “Development of a
dietary-induced metabolic syndrome model using miniature
pigs involvement of AMPK and SIRT1,” European Journal of
Clinical Investigation, vol. 45, no. 1, pp. 70–80, 2015.
[9] Z. P. Neeb, J. M. Edwards, M. Alloosh, X. Long, E. A. Mokelke,
and M. Sturek, “Metabolic syndrome and coronary artery dis-
ease in Ossabaw compared with Yucatan swine,” Comparative
Medicine, vol. 60, no. 4, pp. 300–315, 2010.
[10] L. Lee, M. Alloosh, R. Saxena et al., “Nutritional model of stea-
tohepatitis and metabolic syndrome in the Ossabaw miniature
swine,” Hepatology, vol. 50, no. 1, pp. 56–67, 2009.
[11] S.-J. Li, S.-T. Ding, H. J. Mersmann, C.-H. Chu, C.-D. Hsu, and
C.-Y. Chen, “A nutritional nonalcoholic steatohepatitis mini-
pig model,” The Journal of Nutritional Biochemistry, vol. 28,
pp. 51–60, 2016.
[12] N. Ouchi, J. L. Parker, J. J. Lugus, and K. Walsh, “Adipokines
in inﬂammation and metabolic disease,” Nature Reviews
Immunology, vol. 11, no. 2, pp. 85–97, 2011.
[13] J. M. Olefsky and C. K. Glass, “Macrophages, inﬂammation,
and insulin resistance,” Annual Review of Physiology, vol. 72,
no. 1, pp. 219–246, 2010.
[14] O. Osborn and J. M. Olefsky, “The cellular and signaling net-
works linking the immune system and metabolism in disease,”
Nature Medicine, vol. 18, no. 3, pp. 363–374, 2012.
[15] R. Cancello, C. Henegar, N. Viguerie et al., “Reduction of mac-
rophage inﬁltration and chemoattractant gene expression
changes in white adipose tissue of morbidly obese subjects
after surgery-induced weight loss,” Diabetes, vol. 54, no. 8,
pp. 2277–2286, 2005.
[16] S. Cinti, G. Mitchell, G. Barbatelli et al., “Adipocyte death
deﬁnes macrophage localization and function in adipose tissue
of obese mice and humans,” Journal of Lipid Research, vol. 46,
no. 11, pp. 2347–2355, 2005.
[17] S. P. Weisberg, D. McCann, M. Desai, M. Rosenbaum,
R. L. Leibel, and A. W. Ferrante Jr, “Obesity is associated
with macrophage accumulation in adipose tissue,” The Jour-
nal of Clinical Investigation, vol. 112, no. 12, pp. 1796–1808,
2003.
[18] E. Klimcakova, B. Roussel, Z. Kovacova et al., “Macrophage
gene expression is related to obesity and the metabolic syn-
drome in human subcutaneous fat as well as in visceral fat,”
Diabetologia, vol. 54, no. 4, pp. 876–887, 2011.
[19] J. M. Wentworth, G. Naselli, W. A. Brown et al., “Pro-inﬂam-
matory CD11c+CD206+ adipose tissue macrophages are asso-
ciated with insulin resistance in human obesity,” Diabetes,
vol. 59, no. 7, pp. 1648–1656, 2010.
[20] P. M. Ridker, J. E. Buring, N. R. Cook, and N. Rifai, “C-reactive
protein, the metabolic syndrome, and risk of incident cardio-
vascular events: an 8-year follow-up of 14 719 initially healthy
American women,” Circulation, vol. 107, no. 3, pp. 391–397,
2003.
[21] P. Mathieu, P. Poirier, P. Pibarot, I. Lemieux, and J. P. Despres,
“Visceral obesity: the link among inﬂammation, hypertension,
and cardiovascular disease,” Hypertension, vol. 53, no. 4,
pp. 577–584, 2009.
[22] E. Bonora, S. Del Prato, R. C. Bonadonna et al., “Total body fat
content and fat topography are associated diﬀerently with
in vivo glucose metabolism in nonobese and obese nondiabetic
women,” Diabetes, vol. 41, no. 9, pp. 1151–1159, 1992.
[23] M. Zhang, T. Hu, S. Zhang, and L. Zhou, “Associations of
diﬀerent adipose tissue depots with insulin resistance: a sys-
tematic review and meta-analysis of observational studies,”
Scientiﬁc Reports, vol. 5, article 18495, 2015.
[24] T. Thim, M. K. Hagensen, L. Drouet et al., “Familial hyper-
cholesterolaemic downsized pig with human-like coronary
atherosclerosis: a model for preclinical studies,” EuroInterven-
tion, vol. 6, no. 2, pp. 261–268, 2010.
[25] C. B. Poulsen, A. L. al-Mashhadi, K. von Wachenfeldt et al.,
“Treatment with a human recombinant monoclonal IgG
antibody against oxidized LDL in atherosclerosis-prone pigs
reduces cathepsin S in coronary lesions,” International Journal
of Cardiology, vol. 215, pp. 506–515, 2016.
[26] G. J. Cho, J. H. Lee, H. T. Park et al., “Postmenopausal status
according to years since menopause as an independent risk
factor for the metabolic syndrome,” Menopause, vol. 15,
no. 3, pp. 524–529, 2008.
[27] T. M. Wallace, J. C. Levy, and D. R. Matthews, “Use and abuse
of HOMA modeling,” Diabetes Care, vol. 27, no. 6, pp. 1487–
1495, 2004.
11Journal of Diabetes Research
[28] A. Tura, S. Sbrignadello, E. Succurro, L. Groop, G. Sesti, and
G. Pacini, “An empirical index of insulin sensitivity from short
IVGTT: validation against the minimal model and glucose
clamp indices in patients with diﬀerent clinical characteris-
tics,” Diabetologia, vol. 53, no. 1, pp. 144–152, 2010.
[29] D. Val-Laillet, S. Blat, I. Louveau, and C. H. Malbert, “A com-
puted tomography scan application to evaluate adiposity in a
minipig model of human obesity,” British Journal of Nutrition,
vol. 104, no. 11, pp. 1719–1728, 2010.
[30] A. Etzerodt and S. K. Moestrup, “CD163 and inﬂammation:
biological, diagnostic, and therapeutic aspects,” Antioxidants
& Redox Signaling, vol. 18, no. 17, pp. 2352–2363, 2013.
[31] E. Jobs, U. Risérus, E. Ingelsson et al., “Serum cathepsin S
is associated with decreased insulin sensitivity and the
development of type 2 diabetes in a community-based cohort
of elderly men,” Diabetes Care, vol. 36, no. 1, pp. 163–165,
2013.
[32] N. Naour, C. Rouault, S. Fellahi et al., “Cathepsins in human
obesity: changes in energy balance predominantly aﬀect
cathepsin S in adipose tissue and in circulation,” The Journal
of Clinical Endocrinology & Metabolism, vol. 95, no. 4,
pp. 1861–1868, 2010.
[33] S. Taleb, D. Lacasa, J.-P. Bastard et al., “Cathepsin S, a novel
biomarker of adiposity: relevance to atherogenesis,” The
FASEB Journal, vol. 19, pp. 1540–1542, 2005.
[34] R. L. Wilensky, Y. Shi, E. R. Mohler et al., “Inhibition of
lipoprotein-associated phospholipase A2 reduces complex cor-
onary atherosclerotic plaque development,” Nature Medicine,
vol. 14, no. 10, pp. 1059–1066, 2008.
[35] I. Murano, G. Barbatelli, V. Parisani et al., “Dead adipocytes,
detected as crown-like structures, are prevalent in visceral fat
depots of genetically obese mice,” Journal of Lipid Research,
vol. 49, no. 7, pp. 1562–1568, 2008.
[36] R. H. Al-Mashhadi, C. B. Sørensen, P. M. Kragh et al.,
“Familial hypercholesterolemia and atherosclerosis in cloned
minipigs created by DNA transposition of a human PCSK9
gain-of-function mutant,” Science Translational Medicine,
vol. 5, no. 166, article 166ra1, 2013.
[37] J. S. Long and L. H. Ervin, “Using heteroscedasticity consistent
standard errors in the linear regression model,” The American
Statistician, vol. 54, no. 3, pp. 217–224, 2000.
[38] A. Schiopu, B. Frendéus, B. Jansson et al., “Recombinant anti-
bodies to an oxidized low-density lipoprotein epitope induce
rapid regression of atherosclerosis in Apobec-1−/−/low-density
lipoprotein receptor−/− mice,” Journal of the American College
of Cardiology, vol. 50, no. 24, pp. 2313–2318, 2007.
[39] G. N. Fredrikson, L. Andersson, I. Söderberg et al., “Ather-
oprotective immunization with MDA-modiﬁed apo B-100
peptide sequences is associated with activation of Th2 speciﬁc
antibody expression,” Autoimmunity, vol. 38, no. 2, pp. 171–
179, 2005.
[40] S. Li, P. Kievit, A.-K. Robertson et al., “Targeting oxidized LDL
improves insulin sensitivity and immune cell function in obese
Rhesus macaques,” Molecular Metabolism, vol. 2, no. 3,
pp. 256–269, 2013.
[41] Genentech, A Study to Evaluate the Safety, Tolerability, and
Activity of Intravenous MLDL1278A in Patients on Standard-
of-Care Therapy for Stable Atherosclerotic Cardiovascular
Disease (GLACIER), 2010, Febuary 2014, http://clinicaltrials.
gov/ct2/show/NCT01258907.
[42] K.-A. Lê and L. Tappy, “Metabolic eﬀects of fructose,” Current
Opinion in Clinical Nutrition and Metabolic Care, vol. 9, no. 4,
pp. 469–475, 2006.
[43] S. S. Elliott, N. L. Keim, J. S. Stern, K. Teﬀ, and P. J. Havel,
“Fructose, weight gain, and the insulin resistance syndrome,”
The American Journal of Clinical Nutrition, vol. 76, no. 5,
pp. 911–922, 2002.
[44] P. Gayoso-Diz, A. Otero-Gonzalez, M. X. Rodriguez-Alvarez
et al., “Insulin resistance index (HOMA-IR) levels in a general
adult population: curves percentile by gender and age. The
EPIRCE study,” Diabetes Research and Clinical Practice,
vol. 94, no. 1, pp. 146–155, 2011.
[45] H. C. M. Boonen, S. G. Moesgaard, M. M. Birck et al., “Func-
tional network analysis of obese and lean Göttingen minipigs
elucidates changes in oxidative and inﬂammatory networks
in obese pigs,” Pﬂügers Archiv - European Journal of Physiol-
ogy, vol. 466, no. 12, pp. 2167–2176, 2014.
[46] B. G. Nordestgaard and A. Varbo, “Triglycerides and cardio-
vascular disease,” Lancet, vol. 384, no. 9943, pp. 626–635,
2014.
[47] R. Pedersen, H.-C. Ingerslev, M. Sturek et al., “Characterisa-
tion of gut microbiota in Ossabaw and Göttingen minipigs as
models of obesity and metabolic syndrome,” PLoS One,
vol. 8, no. 2, article e56612, 2013.
[48] F. J. Allan, The Evaluation and Use of the Pig (Sus domesticus)
as a Model for Determining the Eﬀects of Dietary Lipids on
Lipid Metabolism and Thrombosis in Human Beings, Thesis,
Massey University, Palmerston North, 2001.
[49] W. G. Bergen and H. J. Mersmann, “Comparative aspects of
lipid metabolism: impact on contemporary research and use
of animal models,” The Journal of Nutrition, vol. 135, no. 11,
pp. 2499–2502, 2005.
[50] W. M. Rauw, O. Portolés, D. Corella et al., “Behaviour inﬂu-
ences cholesterol plasma levels in a pig model,” Animal,
vol. 1, no. 06, p. 865, 2007.
[51] S. J. Bigornia, M. G. Farb, M. M.Mott et al., “Relation of depot-
speciﬁc adipose inﬂammation to insulin resistance in human
obesity,” Nutrition & Diabetes, vol. 2, no. 3, article e30, 2012.
12 Journal of Diabetes Research
Stem Cells 
International
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
MEDIATORS
INFLAMMATION
of
Endocrinology
International Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
Disease Markers
Hindawi
www.hindawi.com Volume 2018
BioMed 
Research International
Oncology
Journal of
Hindawi
www.hindawi.com Volume 2013
Hindawi
www.hindawi.com Volume 2018
Oxidative Medicine and 
Cellular Longevity
Hindawi
www.hindawi.com Volume 2018
PPAR Research
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2013www.hindawi.com
The Scientific 
World Journal
8
Immunology Research
Hindawi
www.hindawi.com Volume 2018
Journal of
Obesity
Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
 Computational and  
Mathematical Methods 
in Medicine
Hindawi
www.hindawi.com Volume 2018
Behavioural 
Neurology
Ophthalmology
Journal of
Hindawi
www.hindawi.com Volume 2018
Diabetes Research
Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
Research and Treatment
AIDS
Hindawi
www.hindawi.com Volume 2018
Gastroenterology 
Research and Practice
Hindawi
www.hindawi.com Volume 2018
Parkinson’s 
Disease
Evidence-Based 
Complementary and
Alternative Medicine
Volume 2018
Hindawi
www.hindawi.com
Submit your manuscripts at
www.hindawi.com
